Drug development is a multifaceted journey characterized by meticulous research, rigorous testing, and regulatory scrutiny, aiming to bring novel therapeutics to the market to address unmet medical needs and improve patient outcomes. It begins with the identification of a potential target, often a molecule or biological pathway implicated in a disease process, through intensive scientific investigation and analysis of disease mechanisms. This initial stage involves a comprehensive understanding of the pathophysiology and molecular pathways involved, often aided by advanced technologies such as genomics, proteomics, and bioinformatics. Once a target is identified, researchers embark on the arduous task of discovering and designing compounds that can modulate or interact with the target to exert a therapeutic effect.
The process of drug discovery involves various approaches, including screening large libraries of chemical compounds, rational drug design based on structural biology and computational modeling, and leveraging natural products or existing drugs as starting points for optimization. Through iterative cycles of synthesis, testing, and optimization, researchers strive to identify lead compounds with desirable pharmacological properties, such as potency, selectivity, and safety profiles. These lead compounds undergo extensive preclinical evaluation, including in vitro studies and animal models, to assess their efficacy, safety, and pharmacokinetic properties.
Successful lead compounds advance to the clinical development phase, where they undergo rigorous evaluation in human subjects through a series of clinical trials designed to assess safety, efficacy, and optimal dosing regimens. Clinical trials are conducted in multiple phases, starting with Phase I trials focused on safety and pharmacokinetics in healthy volunteers, followed by Phase II trials to evaluate efficacy and dosing in a small cohort of patients with the target disease. Phase III trials involve large-scale studies to confirm efficacy, monitor long-term safety, and establish the benefit-risk profile compared to existing treatments or placebo.
Title : Advances in plasma-based waste treatment for sustainable communities
Hossam A Gabbar, Ontario Tech University, Canada
Title : Nanostructured biodevices based on carbon nanotubes and glyconanoparticles for bioelectrocatalytic applications
Serge Cosnier, Silesian University of Technology, Poland
Title : Carbon capture and storage: The impact of impurities in CO2 streams
Andy Brown, Progressive Energy Ltd, United Kingdom
Title : Supramolecular nano chemistries: Fighting viruses, inhibiting bacteria and growing tissues
Thomas J Webster, Hebei University of Technology, China
Title : Chemical engineering of vanadium and tantalum zeolites for application in environmental catalysis
Stanislaw Dzwigaj, Sorbonne Universite, France
Title : Disrupting TNF-α and TNFR1 interaction: Computational insights into the potential of D-Pinitol as an anti-inflammatory therapeutic
Ferran Acuna Pares, Universidad Internacional de la Rioja (UNIR), Spain